Cancer :: Revlimid patients live longer and remain transfusion free
Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this year’s American Society of Hematology (ASH) meeting.